Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chimerix, Inc. - Common Stock (NQ: CMRX )

3.370 +0.150 (+4.66%)
Streaming Delayed Price Updated: 2:04 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,831,235
Open 3.300
Bid (Size) 3.370 (9)
Ask (Size) 3.380 (3)
Prev. Close 3.220
Today's Range 3.300 - 3.610
52wk Range 0.7500 - 3.390
Shares Outstanding 86,249,744
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
S&P 500 Edges Lower; AutoZone Posts Downbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
+251.04%
+251.04%
1 Month
+272.75%
+272.75%
3 Month
+272.99%
+272.99%
6 Month
+279.03%
+279.03%
1 Year
+255.67%
+255.67%

More News

Read More
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings
Via Benzinga
Dow Falls 150 Points; Oracle Posts Downbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?
Via Benzinga
Exposures Product Safety
CMRX Stock Earnings: Chimerix Misses EPS for Q1 2024
Via InvestorPlace
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
CMRX Stock Earnings: Chimerix Meets EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
Via FinancialNewsMedia
Exposures COVID-19
Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
From FN Media Group LLC
Via GlobeNewswire
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.